Cerus (CERS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting commenced virtually with board and leadership introductions and confirmation of the agenda.
Inspector of Election and independent auditors were introduced, and meeting procedures were outlined.
Notice of meeting and quorum were confirmed, allowing business to proceed.
Board and executive committee updates
Vivek Jayaraman will succeed the current CEO as President and CEO effective July 1st.
Shareholder proposals
Four proposals were presented: election of two directors, amendment of the 2024 Equity Incentive Plan, advisory approval of executive compensation, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cerus
- Q3 2024 product revenue up 16%, net loss narrowed, and full-year guidance raised.CERS
Q3 20248 Jul 2026 - 2025 revenue rose 16% with narrowing losses and surging INTERCEPT Fibrinogen Complex demand.CERSQ4 20258 Jul 2026
- Q2 revenue up 16%, net loss narrowed, and 2024 guidance raised on strong North American growth.CERSQ2 20248 Jul 2026
- BARDA awards up to $248M for U.S. program; Europe plans new submission after CE Mark setback.CERSStudy Update8 Jul 2026
- Q1 2026 revenue up 23%, product revenue up 24%, and net loss narrowed to $1.6 million.CERSQ1 20263 May 2026
- Record revenue growth and global expansion driven by INTERCEPT blood safety technologies.CERSCorporate presentation22 Apr 2026
- Proxy covers director elections, equity plan expansion, pay, auditor, and governance highlights.CERSProxy filing22 Apr 2026
- Virtual vote set for June 2026 on directors, equity plan, pay, and auditor ratification.CERSProxy filing22 Apr 2026
- Record 2025 growth and global expansion highlight strong momentum in blood safety innovation.CERSCorporate presentation9 Mar 2026